{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:16:14Z","timestamp":1791335774008,"version":"4.3.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cllc.2025.08.002","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T23:15:19Z","timestamp":1754522119000},"page":"603-609.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5917-6209","authenticated-orcid":false,"given":"Fangdi","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel J.","family":"Myall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Bolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Riess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie S.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2025.08.002_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.912505","article-title":"Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer","volume":"12","author":"Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.cllc.2025.08.002_bib0002","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.08.002_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-45815-8","article-title":"Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC","volume":"13","author":"Ju","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.cllc.2025.08.002_bib0004","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/JTO.0000000000000669","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors for non-small-cell lung cancer patients with leptomeningeal carcinomatosis","volume":"10","author":"Liao","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.08.002_bib0005","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.08.002_bib0006","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II efficacy and safety of 80 mg Osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2025.08.002_bib0007","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of Osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2025.08.002_bib0008","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/JTO.0000000000000647","article-title":"Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI","volume":"10","author":"Hata","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2025.08.002_bib0009","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00228-020-02926-9","article-title":"Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non-small cell lung cancer (NSCLC) with brain metastases","volume":"76","author":"Shriyan","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.cllc.2025.08.002_bib0010","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","article-title":"Pulsatile\" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer","volume":"13","author":"Grommes","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cllc.2025.08.002_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2018.04.015","article-title":"Phase Ib study of high-dose intermittent Afatinib in patients with advanced solid tumors","volume":"19","author":"Camidge","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2025.08.002_bib0012","article-title":"High-dose Osimertinib for CNS progression in EGFR+ NSCLC: a multi-institutional experience","volume":"3","author":"Piper-Vallillo","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.cllc.2025.08.002_bib0013","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Vol 2024: U.S. Department of Health and Human Services. National Institutes of Health; 2017.Bethesda, Maryland"},{"key":"10.1016\/j.cllc.2025.08.002_bib0014","unstructured":"R Core Team. R: a Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. URL https:\/\/www.R-project.org\/2021."},{"key":"10.1016\/j.cllc.2025.08.002_bib0015","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/neuonc\/noac043","article-title":"Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort","volume":"24","author":"Le Rhun","year":"2022","journal-title":"Neuro Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425001652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730425001652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:03:15Z","timestamp":1778943795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730425001652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1525730425001652"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.08.002","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brief Report: Safety of Pulse-Dose Osimertinib for Treatment of Leptomeningeal Disease or Refractory Brain Metastases in EGFR-Mutated Nonsmall Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}